Trials / Unknown
UnknownNCT04799626
Population Pharmacokinetics and Dosage Individualization of Antibiotics in Elderly Patients
Population Pharmacokinetics and Dosage Individualization of Biapenem,Meropenem,Piperacillin and Tazobactam,Tigecycline,Levofloxacin .Etc in Elderly Patients Who Was Hospitalized in Intensive Care Unit
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Shandong University · Academic / Other
- Sex
- All
- Age
- 65 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The investigator's purpose is to study the pharmacokinetics and pharmacodynamics of biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc in elderly ICU patients and recommend an individual dosage regimen of those antibiotics.
Detailed description
The use of biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc in elderly ICU patients during clinical treatment depended mostly on experience. Besides, there was no recommended dose for elderly patients in drug instruction, Therefore, we aim to study the pharmacokinetics and pharmacodynamics in elderly ICU patients and provide a tailormade regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc | biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment. |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2023-03-30
- Completion
- 2023-06-30
- First posted
- 2021-03-16
- Last updated
- 2022-06-23
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04799626. Inclusion in this directory is not an endorsement.